Navigation Links
European Summit on Cardiovascular Disease Prevention
Date:1/18/2008

Sophia Antipolis, France ---Bridging the unacceptable gap between what is recommended and what is achieved in daily practice regarding the prevention of cardiovascular disease is how Prof Guy De Backer, Chairman of the CVD Prevention Committee of the European Society of Cardiology (ESC), summarises the aim of the European Summit on Cardiovascular Disease Prevention.

Creating incentives for people to make healthy choices in every European country is the difficult task that the 200 delegates of 46 countries and 27 health organisations have undertaken at the European Summit on Cardiovascular Prevention. The meeting takes place today at the Heart House, headquarters of the European Society of Cardiology, located in Sophia-Antipolis, France.

Cardiovascular disease (CVD) causes 49% of deaths in Europe, is the main cause of death in women on this continent and costs the European Union over 169 billion EUR a year. Getting countries to educate their population and allocating an adequate budget to preventive care and rehabilitation is therefore of the utmost importance.

By the end of 2008 all European Countries will have subscribed to the European Heart Health Charter (www.heartcharter.eu) and will have set up a Joint National Task Force to take the necessary actions to implement it.

The Fourth European Task Force has published Guidelines for the Prevention of CVD, which are the result of a unique consensus between experts of different specialities. These guidelines must now be translated and implemented locally, taking into consideration national, cultural and socioeconomic issues.

Schools, hospitals and policy makers are being encouraged to increase their efforts to educate people on the basics of heart disease prevention which include a balanced diet, physical activity and avoidance of tobacco. Actions which lead to the reimbursement of CVD prevention within existing health care
'/>"/>

Contact: Jacqueline Partarrieu
jpartarrieu@escardio.org
33-492-948-627
European Society of Cardiology
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
2. Phylonix granted broad European patent for transplanting human cells into zebrafish
3. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
4. Innocoll Receives Intends to Grant Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology
5. Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008
6. GLOBESCAN Survey for the BEYOND GDP Conference, European Parliament, Nov. 19th and 20th
7. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
8. Living arrangements, health and well-being: A European perspective
9. SPO Medical Unveils New Oximetry Devices for European Markets
10. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
11. Haemonetics Appoints Executive Leadership of European Operations
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7President Announces Free Health Plan 58446 1President Announces Free Health Plan 58446 2President Announces Free Health Plan 58446 3Crisis in Aging 3A Disability and Alzheimer 26apos 3Bs 3A Lack of Caregivers Threatens South Florida Seniors 26apos 3B Ability to Stay Home 58441 1Crisis in Aging 3A Disability and Alzheimer 26apos 3Bs 3A Lack of Caregivers Threatens South Florida Seniors 26apos 3B Ability to Stay Home 58441 2Crisis in Aging 3A Disability and Alzheimer 26apos 3Bs 3A Lack of Caregivers Threatens South Florida Seniors 26apos 3B Ability to Stay Home 58441 3Crisis in Aging 3A Disability and Alzheimer 26apos 3Bs 3A Lack of Caregivers Threatens South Florida Seniors 26apos 3B Ability to Stay Home 58441 4Scientists find obesity alone does not cause arthritis in animals 58436 1Scientists find obesity alone does not cause arthritis in animals 58436 2Scientists find obesity alone does not cause arthritis in animals 58436 3